Ownmed is a Madrid-based spin-off founded in 2021 from a collaboration between the Hospital Gregorio Marañón research foundation (FIBHGM), Fundación Jiménez Díaz research institute and Universidad Carlos III de Madrid. The company develops patient-centered technologies to improve quality of life for people with ostomies; its flagship product, Ostofix, is an easy-to-use anti-reflux device that prevents external leakage and enables syringe-controlled evacuation as an alternative to ostomy bags. The team combines biomedical engineering, clinical expertise and business leadership (CEO Ana Ye; cofounders Dr. Manuel Desco and Dr. Jesús García-Foncillas; CTO Alfredo Azabal; advisor Joaquín Solanes). Ownmed recently closed a €630k investment round to advance product development. GENESIS Biomed has provided business and regulatory support, including business-plan preparation, strategic guidance and accompaniment in a briefing meeting with the AEMPS. Proceeds will fund the design of a functional prototype and the manufacture of multiple devices for clinical comparative validation against existing ostomy bags.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

May 2024